Advanced Asset Management Advisors Inc Invests $276,000 in Eli Lilly and Co (LLY) Stock

Advanced Asset Management Advisors Inc bought a new position in shares of Eli Lilly and Co (NYSE:LLY) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 3,263 shares of the company’s stock, valued at approximately $276,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Eli Lilly and by 2.3% in the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after buying an additional 1,610,885 shares during the period. BlackRock Inc. increased its stake in shares of Eli Lilly and by 2.1% in the second quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock valued at $5,232,942,000 after buying an additional 1,323,259 shares during the period. Janus Henderson Group PLC increased its stake in shares of Eli Lilly and by 16.1% in the third quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock valued at $928,719,000 after buying an additional 1,503,918 shares during the period. Dodge & Cox increased its stake in shares of Eli Lilly and by 22,094.9% in the second quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after buying an additional 5,964,955 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of Eli Lilly and by 91.1% in the second quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock valued at $468,691,000 after buying an additional 2,714,505 shares during the period. 76.20% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have recently issued reports on the company. Credit Suisse Group reaffirmed a “hold” rating and issued a $80.00 price objective on shares of Eli Lilly and in a research note on Friday, February 2nd. Bank of America lowered their price objective on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a research note on Thursday, February 1st. BMO Capital Markets upped their price objective on Eli Lilly and from $73.00 to $74.00 and gave the company an “underperform” rating in a research note on Thursday, February 1st. Jefferies Group set a $100.00 price objective on Eli Lilly and and gave the company a “buy” rating in a research note on Tuesday, January 16th. Finally, Goldman Sachs Group cut Eli Lilly and from a “buy” rating to a “neutral” rating and upped their target price for the company from $86.98 to $95.00 in a report on Tuesday, January 16th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the stock. Eli Lilly and presently has a consensus rating of “Hold” and a consensus target price of $92.02.

In other Eli Lilly and news, SVP Jeffrey N. Simmons sold 9,625 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.12, for a total transaction of $780,780.00. Following the transaction, the senior vice president now directly owns 152,120 shares in the company, valued at approximately $12,339,974.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Susan Mahony sold 36,585 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $86.18, for a total value of $3,152,895.30. Following the transaction, the senior vice president now owns 54,885 shares in the company, valued at $4,729,989.30. The disclosure for this sale can be found here. Insiders have sold a total of 259,610 shares of company stock worth $22,727,406 over the last 90 days. Company insiders own 0.20% of the company’s stock.

Eli Lilly and Co (NYSE:LLY) opened at $78.97 on Friday. The stock has a market capitalization of $86,950.00, a P/E ratio of 49.05, a price-to-earnings-growth ratio of 1.44 and a beta of 0.23. Eli Lilly and Co has a twelve month low of $73.69 and a twelve month high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. The firm had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a positive return on equity of 31.44% and a negative net margin of 0.89%. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the prior year, the business earned $0.95 EPS. sell-side analysts anticipate that Eli Lilly and Co will post 4.87 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.85%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is presently 139.75%.

WARNING: This piece of content was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2018/02/17/advanced-asset-management-advisors-inc-invests-276000-in-eli-lilly-and-co-lly-stock.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply